|Bid||10.31 x 800|
|Ask||11.25 x 3200|
|Day's Range||10.69 - 11.07|
|52 Week Range||9.14 - 20.00|
|Beta (3Y Monthly)||1.28|
|PE Ratio (TTM)||17.80|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Menlo Park, California-based company said it had net income of 15 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The drug developer posted revenue of $64.8 million ...
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. NASDAQ and Russell 2000 indices were already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points in the fourth quarter. Hedge funds and institutional […]
It hasn't been the best quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders, since the share price has fallen 20% in that time. But that scarcely detracts from the really solid long term returns gener...
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Corcept Therapeutics Incorporated (NASDAQ:CORT) is a company with exceptional fundamentalRead More...
Corcept Therapeutics Inc. (CORT) is one of them. Warning! GuruFocus has detected 3 Warning Signs with CORT. With Corcept set to earn upwards of $1 per share in 2019, it is probably fairly valued at its current cap.
The most recent earnings update Corcept Therapeutics Incorporated's (NASDAQ:CORT) released in December 2018 indicated that the business endured a major headwind with earnings deteriorating by -42%. Below, I've presented keyRead More...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! How far off is Corcept Therapeutics Incorporated Read More...
An investigative report is shining light on some very serious questions about the company. Shareholders absolutely must read it.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year. The ...
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]